IB
Impact BioMedical Inc.
IBO · AMEX
$0.49 -1.26% (-$0.01)
1M +16.28%
Market Cap $53.2M
P/E Ratio 67.47x
Div. Yield -
ROE 13.70%
Bulios Fair Price
$0.58
17.5% upside
Current Price
$0.49
Undervalued Fair Value Overvalued
According to Bulios Fair Price, IBO is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
10 /100
Expensive P/S 1,520.90x
P/B 4.94x
P/E 67.47x
Growth
0 /100
Declining Book val. growth 24.72%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak FCF margin 1,451.43%
Op. margin 14,562.90%
Gross margin 1,111.43%
Quality
58 /100
Average Asset turnover 0.00x
ROA 4.71%
ROIC 14.92%
Debt
46 /100
Moderate Current ratio 0.16x
Int. coverage -5.89x
Debt/Equity 0.00x
Stability
1 /100
Unstable EPS volatility 3,173.45%
Profitable years 0
Beta 2.76x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about IBO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Frank D. Heuszel
Employees
2
Headquarters
Houston